Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Neuland Laboratories Limited (NEULANDLAB) - Net Assets
Latest net assets as of September 2025: ₹16.20 Billion INR
Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has net assets worth ₹16.20 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹25.34 Billion) and total liabilities (₹9.14 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹16.20 Billion |
| % of Total Assets | 63.94% |
| Annual Growth Rate | 19.42% |
| 5-Year Change | 93.88% |
| 10-Year Change | 717.0% |
| Growth Volatility | 41.16 |
Neuland Laboratories Limited - Net Assets Trend (2006–2025)
This chart illustrates how Neuland Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neuland Laboratories Limited (2006–2025)
The table below shows the annual net assets of Neuland Laboratories Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹15.25 Billion | +18.87% |
| 2024-03-31 | ₹12.83 Billion | +29.03% |
| 2023-03-31 | ₹9.94 Billion | +18.27% |
| 2022-03-31 | ₹8.41 Billion | +6.87% |
| 2021-03-31 | ₹7.86 Billion | +10.78% |
| 2020-03-31 | ₹7.10 Billion | +1.52% |
| 2019-03-31 | ₹6.99 Billion | +25.31% |
| 2018-03-31 | ₹5.58 Billion | +2.28% |
| 2017-03-31 | ₹5.46 Billion | +192.34% |
| 2016-03-31 | ₹1.87 Billion | +15.47% |
| 2015-03-31 | ₹1.62 Billion | +30.08% |
| 2014-03-31 | ₹1.24 Billion | +24.07% |
| 2013-03-31 | ₹1.00 Billion | +30.94% |
| 2012-03-31 | ₹764.81 Million | +3.40% |
| 2011-03-31 | ₹739.68 Million | +7.36% |
| 2010-03-31 | ₹688.95 Million | -9.12% |
| 2009-03-31 | ₹758.08 Million | +10.38% |
| 2008-03-31 | ₹686.76 Million | +15.08% |
| 2007-03-31 | ₹596.77 Million | +14.09% |
| 2006-03-31 | ₹523.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuland Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 994630000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹9.95 Billion | 65.23% |
| Common Stock | ₹129.00 Million | 0.85% |
| Other Components | ₹5.17 Billion | 33.92% |
| Total Equity | ₹15.25 Billion | 100.00% |
Neuland Laboratories Limited Competitors by Market Cap
The table below lists competitors of Neuland Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Wendy’s Co
NASDAQ:WEN
|
$1.02 Billion |
|
Yellow Cake plc
OTCQX:YLLXF
|
$1.02 Billion |
|
Guangdong Orient Zirconic Ind Sci & Tech Co Ltd
SHE:002167
|
$1.02 Billion |
|
Air France-KLM SA
PINK:AFRAF
|
$1.02 Billion |
|
Bomin Electronics Co Ltd
SHG:603936
|
$1.02 Billion |
|
ARB Corporation Ltd
AU:ARB
|
$1.02 Billion |
|
Lendlease Global Commercial REIT
PINK:LLGCF
|
$1.02 Billion |
|
Avino Silver & Gold Mines Ltd
NYSE MKT:ASM
|
$1.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuland Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,827,048,000 to 15,248,063,000, a change of 2,421,015,000 (18.9%).
- Net income of 2,601,081,000 contributed positively to equity growth.
- Dividend payments of 179,618,000 reduced retained earnings.
- Other comprehensive income decreased equity by 12,698,043,000.
- Other factors increased equity by 12,697,595,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹2.60 Billion | +17.06% |
| Dividends Paid | ₹179.62 Million | -1.18% |
| Other Comprehensive Income | ₹-12.70 Billion | -83.28% |
| Other Changes | ₹12.70 Billion | +83.27% |
| Total Change | ₹- | 18.87% |
Book Value vs Market Value Analysis
This analysis compares Neuland Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 154.97x to 10.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹79.20 | ₹12273.00 | x |
| 2007-03-31 | ₹91.34 | ₹12273.00 | x |
| 2008-03-31 | ₹105.11 | ₹12273.00 | x |
| 2009-03-31 | ₹116.01 | ₹12273.00 | x |
| 2010-03-31 | ₹104.71 | ₹12273.00 | x |
| 2011-03-31 | ₹112.09 | ₹12273.00 | x |
| 2012-03-31 | ₹120.22 | ₹12273.00 | x |
| 2013-03-31 | ₹124.67 | ₹12273.00 | x |
| 2014-03-31 | ₹156.43 | ₹12273.00 | x |
| 2015-03-31 | ₹188.88 | ₹12273.00 | x |
| 2016-03-31 | ₹210.06 | ₹12273.00 | x |
| 2017-03-31 | ₹489.15 | ₹12273.00 | x |
| 2018-03-31 | ₹500.27 | ₹12273.00 | x |
| 2019-03-31 | ₹555.59 | ₹12273.00 | x |
| 2020-03-31 | ₹553.36 | ₹12273.00 | x |
| 2021-03-31 | ₹612.99 | ₹12273.00 | x |
| 2022-03-31 | ₹655.11 | ₹12273.00 | x |
| 2023-03-31 | ₹774.83 | ₹12273.00 | x |
| 2024-03-31 | ₹999.78 | ₹12273.00 | x |
| 2025-03-31 | ₹1188.47 | ₹12273.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuland Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.61%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.43x
- Recent ROE (17.06%) is above the historical average (10.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 11.92% | 3.82% | 1.11x | 2.81x | ₹10.05 Million |
| 2007 | 15.14% | 4.47% | 1.01x | 3.34x | ₹30.70 Million |
| 2008 | 16.53% | 5.21% | 0.75x | 4.24x | ₹44.84 Million |
| 2009 | 15.73% | 3.89% | 0.82x | 4.93x | ₹43.43 Million |
| 2010 | -10.09% | -2.48% | 0.70x | 5.82x | ₹-137.46 Million |
| 2011 | 7.18% | 1.34% | 0.92x | 5.79x | ₹-20.73 Million |
| 2012 | 3.36% | 0.57% | 1.05x | 5.59x | ₹-50.51 Million |
| 2013 | 13.89% | 3.01% | 1.08x | 4.26x | ₹38.80 Million |
| 2014 | 21.62% | 5.76% | 0.96x | 3.90x | ₹144.09 Million |
| 2015 | 9.88% | 3.40% | 0.92x | 3.17x | ₹-1.91 Million |
| 2016 | 14.64% | 5.36% | 0.97x | 2.81x | ₹86.61 Million |
| 2017 | 8.59% | 8.10% | 0.65x | 1.62x | ₹-76.97 Million |
| 2018 | 2.16% | 2.35% | 0.48x | 1.92x | ₹-437.41 Million |
| 2019 | 2.35% | 2.55% | 0.57x | 1.62x | ₹-534.89 Million |
| 2020 | 2.28% | 2.12% | 0.62x | 1.73x | ₹-547.85 Million |
| 2021 | 10.25% | 8.72% | 0.70x | 1.68x | ₹19.85 Million |
| 2022 | 7.59% | 6.91% | 0.67x | 1.65x | ₹-202.28 Million |
| 2023 | 16.45% | 14.09% | 0.73x | 1.59x | ₹641.08 Million |
| 2024 | 23.39% | 19.25% | 0.85x | 1.43x | ₹1.72 Billion |
| 2025 | 17.06% | 17.61% | 0.68x | 1.43x | ₹1.08 Billion |
Industry Comparison
This section compares Neuland Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuland Laboratories Limited (NEULANDLAB) | ₹16.20 Billion | 11.92% | 0.56x | $1.02 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |